Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 7326 - 7350 of 8341 in total
Lapaquistat is under investigation in clinical trial NCT00256178 (Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia.).
Investigational
Matched Description: … Lapaquistat is under investigation in clinical trial NCT00256178 (Efficacy of Lapaquistat Acetate and …
Nidufexor is under investigation in clinical trial NCT03804879 (Safety, Tolerability and Efficacy of LMB763 in Patients With Diabetic Nephropathy).
Investigational
Matched Description: … Nidufexor is under investigation in clinical trial NCT03804879 (Safety, Tolerability and Efficacy of
TAK-653 is under investigation in clinical trial NCT03312894 (Efficacy and Safety of TAK-653 in Treatment-resistant Depression).
Investigational
Matched Description: … TAK-653 is under investigation in clinical trial NCT03312894 (Efficacy and Safety of TAK-653 in Treatment-resistant …
Coprelotamab is under investigation in clinical trial NCT04170595 (Clinical Study of Recombinant Anti-her2 Humanized Monoclonal Antibody for Injection).
Investigational
Matched Description: … Coprelotamab is under investigation in clinical trial NCT04170595 (Clinical Study of Recombinant Anti-her2 …
Zotatifin is under investigation in clinical trial NCT04092673 (Study of Eft226 in Subjects With Selected Advanced Solid Tumor Malignancies).
Investigational
Matched Description: … Zotatifin is under investigation in clinical trial NCT04092673 (Study of Eft226 in Subjects With Selected …
Uliledlimab is under investigation in clinical trial NCT04322006 (A Phase I/II Study of TJ004309 for Advanced Solid Tumor).
Investigational
Matched Description: … Uliledlimab is under investigation in clinical trial NCT04322006 (A Phase I/II Study of TJ004309 for …
Lirentelimab is under investigation in clinical trial NCT04856891 (A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis).
Investigational
Matched Description: … Lirentelimab is under investigation in clinical trial NCT04856891 (A Study of Lirentelimab (AK002) in …
A recombinant AAVrh74 gene therapy expressing the dysferlin transgene under control of a muscle-specific promoter (rAAVrh74.MHCK7.DYSF.DV).
Investigational
Matched Description: … A recombinant AAVrh74 gene therapy expressing the dysferlin transgene under control of a muscle-specific …
JNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment of narcolepsy.
Investigational
Matched Description: … JNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment of
ORC-13661 is under investigation in clinical trial NCT05730283 (Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin).
Investigational
Matched Description: … ORC-13661 is under investigation in clinical trial NCT05730283 (Prevention of Ototoxicity in NTM Patients …
Gefurulimab is under investigation in clinical trial NCT05556096 (Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis).
Investigational
Matched Description: … Gefurulimab is under investigation in clinical trial NCT05556096 (Safety and Efficacy of ALXN1720 in …
Posdinemab is under investigation in clinical trial NCT04619420 (A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease).
Investigational
Matched Description: … Posdinemab is under investigation in clinical trial NCT04619420 (A Study of JNJ-63733657 in Participants …
Elebsiran is under investigation in clinical trial NCT05461170 (SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.).
Investigational
Matched Description: … under investigation in clinical trial NCT05461170 (SOLSTICE: Combination Therapy for the Treatment of
Emoxypine is under investigation in clinical trial NCT06221826 (MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure).
Investigational
Matched Description: … Emoxypine is under investigation in clinical trial NCT06221826 (MEXIDOL® in the Rehabilitation Treatment of
A narcotic antagonist similar in action to naloxone. It is used to remobilize animals after etorphine neuroleptanalgesia and is considered a specific antagonist to etorphine. [PubChem]
Illicit
Vet approved
5-methyltetrahydrofolic acid is a methylated derivate of tetrahydrofolate. It is generated by methylenetetrahydrofolate reductase from 5,10-methylenetetrahydrofolate and used to recycle homocysteine back to methionine by 5-methyltetrahydrofolate-homocysteine methyltransferases (also called methionine synthases).
Investigational
Nutraceutical
Matched Description: … 5-methyltetrahydrofolic acid is a methylated derivate of tetrahydrofolate. …
HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies. It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.
Investigational
Matched Description: … It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial. …
Ethylene oxide/propylene oxide copolymer is used as a food additive. It belongs to the family of Epoxides. These are compounds containing a cyclic ether with three ring atoms (one oxygen and two carbon atoms).
Investigational
Vet approved
Matched Description: … It belongs to the family of Epoxides. …
Sulfaquinoxaline is a veterinary medicine which can be given to cattle and sheep to treat coccidiosis.It is available in Pakistan with Sanna Laboratories in combination with Amprolium and Vitamin K as potential treatment of coccidiosis.
Vet approved
Matched Description: … Pakistan with Sanna Laboratories in combination with Amprolium and Vitamin K as potential treatment of
Dasotraline is a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI) that is under investigation for the treatment of Binge Eating Disorder, Adult Attention Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder, and Adult Attention Deficit Hyperactivity Disorder.
Investigational
Matched Description: … norepinephrine and dopamine reuptake inhibitor (SNDRI) that is under investigation for the treatment of
RGX-111 is an adeno-associated virus vector AAV9 designed to deliver the α-L-iduronidase (IDUA) gene. Developed by REGENXBIO Inc., it was investigated for the treatment of mucopolysaccharidosis Type I (MPS I).
Investigational
Matched Description: … ., it was investigated for the treatment of mucopolysaccharidosis Type I (MPS I).[L46666] …
Nemtabrutinib is under investigation in clinical trial NCT05624554 (A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)).
Investigational
Matched Description: … Nemtabrutinib is under investigation in clinical trial NCT05624554 (A Study of Nemtabrutinib vs Chemoimmunotherapy …
Plamotamab is under investigation in clinical trial NCT05328102 (Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)).
Investigational
Matched Description: … Plamotamab is under investigation in clinical trial NCT05328102 (Phase 2 Study of Plamotamab Combined …
Dendritic cells (DCs) can be derived and differentiated from peripheral blood mononuclear cells in the presence of specific cytokines and growth factors. These cells are then loaded with antigens produced by a virus or tumor cell and administered as a vaccine. Dendritic Cells (DCs) are showing potential as natural adjuvants...
Investigational
Matched Description: … and immunogenicity of the vaccine. ... cells (DCs) can be derived and differentiated from peripheral blood mononuclear cells in the presence of ... As of May 2020, the company is pursuing a human clinical trial (ChiCTR2000033003) to test the safety …
The University of Queensland (UQ), in partnership with The Coalition for Epidemic Preparedeness Inovations (CEPI) and CSL has developed a COVID-19 candidate, SARS-CoV-2 Sclamp. The vaccine was developed using UQ’s rapid response ‘molecular clamp’ vaccine platform that locks surface proteins in a configuration that allows more robust immune responses, in...
Investigational
Matched Description: … The University of Queensland (UQ), in partnership with The Coalition for Epidemic Preparedeness Inovations ... Preclinical trials showed the vaccine candidate produced high levels of neutralizing antibodies, and ... As of July 13, 2020, the candidate is being tested for safety and immunogenicity in Phase 1 clinical …
Displaying drugs 7326 - 7350 of 8341 in total